Comparative Pharmacology
Head-to-head clinical analysis: MYCELEX G versus SELENIUM SULFIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCELEX G versus SELENIUM SULFIDE.
MYCELEX-G vs SELENIUM SULFIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Selenium sulfide is an antifungal and cytostatic agent. It reduces sebum production and inhibits the growth of Malassezia species by interfering with fungal lipid metabolism and cell wall synthesis. The exact molecular mechanism is not fully elucidated.
Clotrimazole 100 mg vaginal tablet inserted intravaginally once daily for 7 days or 200 mg once daily for 3 days; or 500 mg single dose. Also available as 1% vaginal cream, 1 applicatorful (5 g) intravaginally once daily for 7-14 days.
Topical: 2.5% lotion or shampoo applied to affected area once daily for 7 days; 1% shampoo used once or twice weekly for maintenance.
None Documented
None Documented
Biphasic: initial half-life ~30 minutes, terminal half-life ~30 hours; clinical significance: supports once-daily dosing for topical/vaginal formulations.
Not established; due to negligible systemic absorption, a terminal half-life is not clinically relevant. If absorbed, selenium has a long biological half-life of approximately 65–115 days due to incorporation into selenoproteins.
Primarily hepatic metabolism; about 80-90% of dose excreted as metabolites in feces via biliary excretion, less than 1% unchanged in urine.
Selenium sulfide is minimally absorbed after topical application. The small absorbed fraction is excreted renally as selenite or selenate, with fecal excretion of unabsorbed drug accounting for >90% of the dose.
Category C
Category A/B
Antifungal
Antifungal / Antiseborrheic